Topics
-
ANTITRUST
-
Asset Management
-
Data, Privacy & Cybersecurity
-
Digital Health
-
Employee Benefits/ERISA
-
Enforcement
-
False Claims Act
-
FDA REGULATORY
- Health Care
-
Intellectual Property
-
PRIVATE EQUITY
-
TAX
Capital Insights
Analysis
- Justice Department Announces New Policies Impacting Corporate Criminal Enforcement
(March 7, 2023) - U.S. Life Sciences Outlook 2023 (Part IV): Additional Insights on Expected Developments
(March 1, 2023) - Russia/Ukraine Crisis: U.S. Announces New Tranche of Sanctions and Export Controls
(February 27, 2023) - U.S. Life Sciences Outlook 2023 (Part III): Agency Litigation Challenges
(February 27, 2023) - U.S. Life Sciences Outlook 2023 (Part II): Anticipated Agency Policy Developments
(February 23, 2023)
In The News
- Matt Rizzolo Moderates Two Panels at American Conference Institute’s Think Tank on International Trade Commission Litigation & Enforcement
(March 31, 2023) - Beth Weinman Presents on Considerations in Shift Toward U.S. Pharmaceutical Manufacturing
(March 30, 2023) - In Bloomberg Law, Margaux Hall Discusses Drugmaker Data Protection in Medicare Price Negotiation Guidance
(March 20, 2023) - In Bloomberg Law and Managing Intellectual Property, Scott McKeown Discusses Federal Circuit Challenge to Patent Review Rules
(March 16, 2023) - In Law360, Matt Rizzolo Discusses Implications in COVID-19 Vaccine IP Government Contract Case
(March 7, 2023)